Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARGS > SEC Filings for ARGS > Form 8-K on 6-Mar-2017All Recent SEC Filings

Show all filings for ARGOS THERAPEUTICS INC

Form 8-K for ARGOS THERAPEUTICS INC


6-Mar-2017

Termination of a Material Definitive Agreement, Financial Statements and E


Item 1.02 Termination of a Material Definitive Agreement.

On March 3, 2017, Argos Therapeutics, Inc. (the "Company") entered into a payoff letter with Horizon Credit II LLC ("HCII"), as assignee of Horizon Technology Finance Corporation ("Horizon"), Fortress Credit Opportunities V CLO Limited ("FCO V"), as assignee of Fortress Credit Co LLC ("Fortress"), Fortress Credit Opportunities VII CLO Limited, as assignee of Fortress ("FCO VII" and collectively with, HCII and FCO V, "Lenders") and Horizon as Collateral Agent, pursuant to which it agreed to pay off and thereby terminate its Venture Loan and Security Agreement dated as of September 29, 2014, as amended, with the Lenders and Horizon as Collateral Agent (the "Loan Agreement").

Pursuant to the payoff letter, the Company will pay, on or about March 6, 2017, a total of $23.1 million to the Lenders, representing the principal balance and accrued interest outstanding under the Loan Agreement in repayment of the Company's outstanding obligations under the Loan Agreement. In addition, the Company will issue to the Lenders five year warrants to purchase an aggregate of 100,000 shares of the Company's Common Stock at an exercise price of $1.30 per share in consideration of the Lenders accepting the $23.1 million.

Upon the payment of the $23.1 million and the issuance of the warrants pursuant to the payoff letter, all outstanding indebtedness and obligations of the Company owing to the Lenders under the Loan Agreement will be deemed paid in full, and the Loan Agreement and the notes thereunder will be terminated.

The Company originally entered into the Loan Agreement in September 2014 and borrowed $25 million over two equal tranches in September 2014 and August 2015. As of March 3, 2017, the Company had repaid to the Lenders $2.1 million in principal under the terms of the Loan Agreement. In addition to principal and interest, the Company had agreed to make a final payment to the Lenders of $625,000 on the maturity date of each tranche loan and prepayment penalty fees, as applicable. The Company's obligations under the Loan Agreement were secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.

The descriptions of the payoff letter and the warrants contained herein do not purport to be complete and are qualified in their entirety by reference to the payoff letter and the warrants, copies of which are attached hereto as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, and are incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

10.1 Payoff Letter, entered into as of March 3, 2017, among Argos Therapeutics, Inc. and the lenders under the Venture Loan and Security Agreement, dated as of September 29, 2014

10.2 Warrant issued to Horizon Technology Finance Corporation, dated March 3, 2017

10.3 Warrant issued to Fortress Credit Opportunities V CLO Limited, dated March 3, 2017

10.4 Warrant issued to Fortress Credit Opportunities VII CLO Limited, dated March 3, 2017

  Add ARGS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARGS - All Recent SEC Filings
Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.